Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panion begins gene therapy safety study in dogs

Swedish firm Panion Animal Health has started a safety study for its canine gene therapy candidate at the University of Copenhagen in Denmark.

Panion is developing the treatment for dogs with drug-resistant epilepsy. The company is moving its R&D work into the clinical stage and the findings will supplement safety data from a previous dog study "that was very encouraging".

The new study will be led by associate professor David Woldbye, who Panion said is an expert in development of gene therapy for treatment of epilepsy.

Panion also recently gained positive results in an efficacy study of its gene therapy candidate – CG01 canine. Panion has a license agreement for dogs and cats with its parent company CombiGene, which is developing a gene therapy approach for the treatment of human epilepsy. CombiGene's work was originally based on discoveries made at the University of Copenhagen and Sweden's Lund University.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AP014019

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel